-+ 0.00%
-+ 0.00%
-+ 0.00%

NeoGenomics highlights MERIDIAN Phase II ctDNA MRD trial data at AACR 2026

PUBT·04/13/2026 11:07:59
Listen to the news
NeoGenomics highlights MERIDIAN Phase II ctDNA MRD trial data at AACR 2026
  • NeoGenomics flagged new clinical trial research on ctDNA-guided molecular residual disease interception in locoregionally advanced head and neck squamous cell carcinoma from MERIDIAN Phase II trial.
  • Results have not been presented yet; oral presentation scheduled at AACR Annual Meeting 2026 in San Diego on April 20.
  • Company positioned study as supporting earlier identification of residual disease to inform clinical decision-making in this cancer setting.
  • NeoGenomics also outlined broader oncology data work combining lab testing with real-world clinical data to support biomarker characterization and AI-driven analysis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604130705BIZWIRE_USPR_____20260413_BW874087) on April 13, 2026, and is solely responsible for the information contained therein.